Intermittent Endocrine Treatment of Prostate Cancer
Authors:
V. Vachalovský; J. Dvořáček
Authors‘ workplace:
Urologická klinika 1. LF UK a VFN, Praha
Published in:
Čas. Lék. čes. 2002; : 669-672
Category:
Overview
Intermittent endocrine treatment or cyclic therapy of prostate cancer aims at prolonging survival by delayingprogression to androgene independence and at improving quality of life by avoiding the side effects of continuousandrogen ablation. Intermittent endocrine treatment is capable of inducing multiple apoptoic regressions and ofimprovement in quality of life including sexual functions. The recommended lenght of therapeutic period is 6–9months. The mean off-therapy interval approaches 50 % of the duration of the treatment cycle. The mean time todisease progression is 32 month. The definitive answer to the question of prolonged survival awaits the completionof ongoing randomized studies.
Key words:
prostate cancer, intermittent androgen treatment.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Phone Survey of the Home Prostitution
- Intermittent Endocrine Treatment of Prostate Cancer
- Effects of Non-Steroidal Anti-Inflammatory Drugs to the GastrointestinalTract
- Contemporary Possibilities of Vascular Surgery